CAS No.50-49-7,IMIPRAMINE Suppliers

Products Categories

Pharmaceutical (39)
Others (17)
Organic Chemicals (5)
Reagent (2)
Materials (1)

Basic Information

Molecular Structure:
CAS No.:	50-49-7
Name:	IMIPRAMINE
Article Data:	30

Formula:	C19H24 N2
Molecular Weight:	280.413
Synonyms:	5H-Dibenz[b,f]azepine,5-[3-(dimethylamino)propyl]-10,11-dihydro- (7CI,8CI); 1-(3-Dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine;5,6-Dihydro-N-[3-(dimethylamino)propyl]-11H-dibenz[b,e]azepine;5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenz[b,f]azepine; Antideprin;Berkomine; Cristalia; Imipramine; Melipramine; N-(3-Dimethylaminopropyl)-o-iminodibenzyl;N-(g-Dimethylaminopropyl)iminodibenzyl;NSC 169866; Org 2463; Prazepine; Sermonil
Density:	1.041g/cm³
Melting Point:	174°C
Boiling Point:	403.1°Cat760mmHg
Flash Point:	179.7°C
Solubility:	18.23mg/L(24 oC)
Safety:	A human poison by ingestion. An experimental poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Human systemic effects by ingestion: somnolence, hallucinations, distorted perceptions, changes in motor activity, ataxia (loss of muscle coordination), coma, nausea and vomiting, irritative dermatitis. An experimental teratogen by ingestion. Other experimental reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of NO_x.
PSA:	6.48000
LogP:	3.94000

Synthetic route

: 6829-98-7
imipramine N-oxide

: 50-49-7
impramine

Conditions

Conditions	Yield
With sodium tetrahydroborate In water at 50 - 60℃; chemoselective reaction;	96%

: 50-47-5
desipramine

: 124-38-9
carbon dioxide

: 50-49-7
impramine

Conditions

Conditions	Yield
With hydrogen In octane at 150℃; for 30h; Autoclave;	89%
With hydrogen; tris(acetylacetonato)ruthenium(III); lithium chloride; [2-((diphenylphospino)methyl)-2-methyl-1,3-propanediyl]bis[diphenylphosphine] In tetrahydrofuran at 140℃; for 24h; Autoclave; Inert atmosphere;	83 %Chromat.
With proazaphosphatrane; 9-bora-bicyclo[3.3.1]nonane In tetrahydrofuran at 90℃; under 750.075 Torr; for 1h; Inert atmosphere; Schlenk technique; chemoselective reaction;	99 %Spectr.

: 876124-39-9
N'-(4-carbomethoxy)desimipramine

: 50-49-7
impramine

Conditions

Conditions	Yield
With lithium aluminium tetrahydride In tetrahydrofuran for 0.5h; Heating;	79%

: 50-00-0
formaldehyd

: 2095-95-6
didesmethylimipramine

: 50-49-7
impramine

Conditions

Conditions	Yield
With formic acid In water at 100℃; for 1h; Eschweiler-Clark Amine Methylation; Microwave irradiation;	61%

: 59485-34-6
1,2-bis(2-bromophenyl)ethane

: 109-55-7
1-amino-3-(dimethylamino)propane

: 50-49-7
impramine

Conditions

Conditions	Yield
With tris-(dibenzylideneacetone)dipalladium(0); sodium t-butanolate; XPhos In toluene at 110℃; Buchwald-Hartwig Coupling;	60%

: 67-56-1
methanol

: 50-47-5
desipramine

: 50-49-7
impramine

Conditions

Conditions	Yield
With rhodium(III) chloride hydrate; potassium tert-butylate at 150℃; for 60h; Sealed tube; High pressure;	49%

: 303-49-1
Clomipramine

A: 14171-67-6
clomipramine N-oxide

B: 50-49-7
impramine

C: 3-hydroxyimipramine

D: 3-hydroxyimipramine-N-oxide

Conditions

Conditions	Yield
With oxygen In methanol; phosphate buffer at 25 - 28℃; pH=7.4; Product distribution; Further Variations:; Reagents; Photolysis; UV-irradiation;	A 15% B 15% C 40% D 20%

...Expand

: 494-19-9
9,10-dihydrodibenzazepine

: 50-49-7
impramine

Conditions

Conditions	Yield
With sodium amide; benzene und Erwaermen der Reaktionsloesung mit <3-Chlor-propyl>-dimethyl-amin;

: 494-19-9
9,10-dihydrodibenzazepine

: 109-54-6
3-(Dimethylamino)propyl chloride

: 50-49-7
impramine

Conditions

Conditions	Yield
With sodium hydroxide; potassium carbonate DMSO 1.) room temp., 2 h, 2.) 110 deg C, 18 h; Yield given. Multistep reaction;
With potassium hydroxide; ammonium acetate In toluene at 20℃; Heating / reflux;

: 124-38-9
carbon dioxide

: [3-(10,11-Dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-methyl-trimethylsilanyl-amine

: 50-49-7
impramine

Conditions

Conditions	Yield
With lithium aluminium tetrahydride 1.) THF, -45 deg C - 60 deg C, 2.) 60 deg C, 10 min; Yield given. Multistep reaction;

Raw Materials

494-19-9

50-47-5

79-22-1

58-28-6

6829-98-7

109-54-6

124-38-9

Downstream Products

303-70-8

10075-24-8

796-28-1

6829-98-7

50-47-5

Total:60 Page 1 of 2 1 2 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 50-49-7

Chemistry

Molecular Structure of Imipramine (CAS NO.50-49-7):

Molecular Formula: C₁₉H₂₄N₂
Molecular Weight: 280.41
IUPAC Name: 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-Dimethylpropan-1-amine
Synonyms of Imipramine (CAS NO.50-49-7): Imipramine ; Aurora ka-7708 ; 1-(3-Dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine ; 10,11-Dihydro-5-(3-(dimethylamino)propyl)-5H-dibenz[b,f]azepine ; 2,2'-(3-Dimethylaminopropylimino)bibenzyl ; 2,2'-(3-Dimethylaminopropylimino)dibenzyl ; 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine ; 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine
CAS NO: 50-49-7
EINECS: 200-042-1
Mol File: 50-49-7.mol
Index of Refraction: 1.574
Surface Tension: 40.1 dyne/cm
Density: 1.041 g/cm³
Flash Point: 179.7 °C
Enthalpy of Vaporization: 65.43 kJ/mol
Boiling Point: 403.1 °C at 760 mmHg
Vapour Pressure: 1.04E-06 mmHg at 25°C
Properties: white or light yellow crystalline powder, no smell, taste and burning hemp.
Solubility: soluble in water, ethanol; almost insoluble in ether.

Uses

Imipramine (CAS NO.50-49-7) is commonly used as antidepressants of tricyclic .

Toxicity Data With Reference

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
cat	LDLo	intravenous	20mg/kg (20mg/kg)		Bollettino Chimico Farmaceutico. Vol. 112, Pg. 601, 1973.
cat	LDLo	oral	100mg/kg (100mg/kg)		Zentralblatt fuer Pharmazie, Pharmakotherapie und Laboratoriums-diagnostik. Vol. 114, Pg. 787, 1975.
child	LD50	oral	40mg/kg (40mg/kg)	BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: COMA	Handbook of Experimental Pharmacology. Vol. 55, Pg. 527, 1980.
child	LDLo	oral	35mg/kg (35mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA CARDIAC: OTHER CHANGES	Schweizerische Medizinische Wochenschrift. Vol. 99, Pg. 1157, 1969.
child	TDLo	oral	30mg/kg (30mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: ATAXIA	American Journal of Diseases of Children. Vol. 130, Pg. 507, 1976.
dog	LDLo	intravenous	45mg/kg (45mg/kg)	PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION	Bollettino Chimico Farmaceutico. Vol. 112, Pg. 601, 1973.
dog	LDLo	oral	100mg/kg (100mg/kg)		"Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 78, 1972.
human	LD50	oral	40mg/kg (40mg/kg)		Proceedings of the European Society for the Study of Drug Toxicity. Vol. 6, Pg. 171, 1965.
human	LDLo	oral	450mg/kg (450mg/kg)	SKIN AND APPENDAGES (SKIN): "DERMATITIS, IRRITATIVE: AFTER SYSTEMIC EXPOSURE"	British Medical Journal. Vol. 1, Pg. 722, 1979.
mammal (species unspecified)	LD50	oral	350mg/kg (350mg/kg)	BEHAVIORAL: ANTICONVULSANT	Journal of Medicinal Chemistry. Vol. 8, Pg. 836, 1965.
mammal (species unspecified)	LD50	unreported	455mg/kg (455mg/kg)		Khimiko-Farmatsevticheskii Zhurnal. Chemical Pharmaceutical Journal. For English translation, see PCJOAU. Vol. 24(7), Pg. 27, 1990.
man	LD50	oral	30mg/kg (30mg/kg)	BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: COMA	Handbook of Experimental Pharmacology. Vol. 55, Pg. 527, 1980.
man	LDLo	oral	71mg/kg (71mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD CARDIAC: CHANGE IN RATE ENDOCRINE: CHANGE IN LH	Journal of Toxicology, Clinical Toxicology. Vol. 19, Pg. 239, 1982.
man	TDLo	oral	5357ug/kg/5D- (5.357mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CHANGE IN REM SLEEP (HUMAN)	Human Psychopharmacology. Vol. 11, Pg. 211, 1996.
man	TDLo	oral	8mg/kg/3D-I (8mg/kg)	BEHAVIORAL: EXCITEMENT	Lancet. Vol. 2, Pg. 568, 1959.
man	TDLo	oral	71428ug/kg/10 (71.428mg/kg)	BEHAVIORAL: REGIDITY SKIN AND APPENDAGES (SKIN): SWEATING: OTHER	Intensive Care Medicine. Vol. 23, Pg. 480, 1997.
mouse	LD50	intraperitoneal	51600ug/kg (51.6mg/kg)		British Patent Document. Vol. #1460700,
mouse	LD50	intravenous	21mg/kg (21mg/kg)	AUTONOMIC NERVOUS SYSTEM: PARASYMPATHOLYTIC BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: WAKEFULNESS	Archives Internationales de Pharmacodynamie et de Therapie. Vol. 245, Pg. 283, 1980.
mouse	LD50	oral	188mg/kg (188mg/kg)	SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)	Pharmaceutical Chemistry Journal Vol. 14, Pg. 773, 1980.
mouse	LD50	subcutaneous	195ug/kg (0.195mg/kg)	BEHAVIORAL: WAKEFULNESS	Pharmaceutical Chemistry Journal Vol. 15, Pg. 412, 1981.
mouse	LD50	unreported	107mg/kg (107mg/kg)	AUTONOMIC NERVOUS SYSTEM: "SMOOTH MUSCLE RELAXANT (MECHANISM UNDEFINED, SPASMOLYTIC)"	Journal of Medicinal Chemistry. Vol. 10, Pg. 418, 1967.
rabbit	LD50	intravenous	18mg/kg (18mg/kg)		Archives Internationales de Pharmacodynamie et de Therapie. Vol. 120, Pg. 450, 1959.
rabbit	LD50	oral	385mg/kg (385mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 19, Pg. 1617, 1969.
rat	LD50	intraperitoneal	79mg/kg (79mg/kg)		Archives Internationales de Pharmacodynamie et de Therapie. Vol. 148, Pg. 560, 1964.
rat	LD50	intravenous	9300ug/kg (9.3mg/kg)		United States Patent Document. Vol. #4141993,
rat	LD50	oral	250mg/kg (250mg/kg)	SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)	Pharmaceutical Chemistry Journal Vol. 14, Pg. 773, 1980.
rat	LD50	subcutaneous	250mg/kg (250mg/kg)		Archives Internationales de Pharmacodynamie et de Therapie. Vol. 148, Pg. 560, 1964.
women	LDLo	oral	2mg/kg/1D (2mg/kg)	LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	Journal of Pharmacy and Pharmacology. Vol. 16, Pg. 265, 1964.
women	TDLo	oral	3mg/kg/32H-I (3mg/kg)	SKIN AND APPENDAGES (SKIN): PHOTOSENSITIVITY: AFTER SYSTEMIC EXPOSURE	JAMA, Journal of the American Medical Association. Vol. 254, Pg. 357, 1985.
women	TDLo	oral	150mg/kg (150mg/kg)	BEHAVIORAL: COMA CARDIAC: OTHER CHANGES VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION	Journal of Toxicology, Clinical Toxicology. Vol. 33, Pg. 51, 1995.

Consensus Reports

EPA Genetic Toxicology Program.

Safety Profile

A human poison by ingestion. An experimental poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Human systemic effects by ingestion: somnolence, hallucinations, distorted perceptions, changes in motor activity, ataxia (loss of muscle coordination), coma, nausea and vomiting, irritative dermatitis. An experimental teratogen by ingestion. Other experimental reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of NO_x.